Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Grapiprant
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : EIC Fund
Deal Size : $27.7 million
Deal Type : Series A Financing
Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing
Details : The financing aims to fund the development of AT-001 an oral treatment designed to prevent the aggregation of harmful amyloid proteins in the brain. It is being evaluated for treating HCCAA.
Product Name : AT-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 22, 2025
Lead Product(s) : Grapiprant
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : EIC Fund
Deal Size : $27.7 million
Deal Type : Series A Financing